Corporación Andina de Fomento (CAF)’s Investment Patia Biopharma

Nader, Hayaux & Goebel advised the Corporación Andina de Fomento on the transaction

Corporación Andina de Fomento (CAF) executed its investment in Patia Biopharma.

Proceeds will be used to develop the “DIABEVID” test, a cost-effective genetic test to identify diabetic patients at high risk of contracting SARS-Cov-2.

Nader, Hayaux & Goebel advised the Corporación Andina de Fomento on the transaction with a team including José Humberto Rocha Saade (Picture) and José María Castro Farrés

Involved fees earner: José María Castro Farrés – Nader, Hayaux & Goebel; José Humberto Rocha – Nader, Hayaux & Goebel;

Law Firms: Nader, Hayaux & Goebel;

Clients: Corporación Andina de Fomento (CAF);

Avatar

Author: Ambrogio Visconti